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Figure	  S1.	  Generation	  of	  PKN1,	  PKN2	  and	  PKN3	  knockouts,	  related	  to	  figure	  1.	  Schematic	  
representation	  of	  the	  wild-­‐type	  (wt)	  and	  targeted	  alleles	  for	  the	  three	  mouse	  PKN	  genes.	  For	  
PKN1	  (A)	  and	  PKN3	  (B)	  a	  representation	  of	  the	  targeting	  construct	  is	  also	  provided.	  The	  PKN2	  
tm1a	   allele	   is	   a	   knockout	   first	   allele	   obtained	   from	   the	   KOMP	   consortium	   (C).	   WT	   and	  
targeted	  alleles	  for	  each	  of	  the	  three	  PKN	  isoforms	  can	  be	  distinguished	  by	  PCR	  (right	  hand	  
panels).	  The	  position	  of	  the	  primers	  used	  for	  PCR	  are	  indicated	  on	  the	  schematic	  and	  details	  
of	   the	  primers	  and	  product	   sizes	  are	  provided	   in	   supplementary	  experimental	  procedures.	  
RT-­‐PCR	  demonstrating	  disruption	  of	  PKN1	  and	  PKN3	  mRNA	  extracted	  from	  mouse	  lungs	  (D).	  
Specific	   primers	   used	   are	   detailed	   in	   supplementary	   experimental	   procedures.	   PKN	  
expression	   in	   wt	   and	   PKN1	   knockout	   (-­‐/-­‐)	   mouse	   embryo	   extracts	   was	   assessed	   by	  
immunoblot	   (E).	  PKN3	  was	  undetectable	   in	  mouse	  embryos	  but	  could	  be	  detected	  using	  a	  
phospho-­‐PKN	  specific	  antibody	  in	  mouse	  lung	  extracts	  (F)	  and	  mouse	  lung	  endothelial	  cells	  
(G).	   To	   positively	   identify	   PKN3,	   protein	  was	   depleted	   by	   siRNA	   from	  murine	   EOMA	   cells.	  
Detection	  of	  α-­‐tubulin	  was	  used	  to	  control	  for	  protein	  loading.	  	  
	  
	  






































































































Figure	   S2.	   PKN2	   is	   broadly	   expressed	   and	   is	   required	   in	   the	   embryo	   proper,	   related	   to	  
figure	   1.	   PKN2	   protein	   is	   expressed	   in	   the	   embryo	   and	   yolk	   sac	   (A)	   and	   is	   expressed	   at	  
approximately	  half	  wild-­‐type	  levels	  in	  heterozygous	  embryos	  (B);	  error	  bars	  represent	  S.D.;	  *	  
<	  P	  0.05,	  n=4).	  A	  single	  tetraploid	  rescue	  litter	  comprising	  two	  wild-­‐type,	  two	  heterozygous	  
and	   two	   knockout	   embryos	   (C).	   Genotypes	   were	   determined	   directly	   from	   genomic	   DNA	  
isolated	   from	   the	   embryos.	   To	   assay	   for	   PKN2	   protein,	   embryo	   lysates	  were	   subjected	   to	  
Western	   blot	   analysis	   and	  α-­‐Tubulin	  was	   used	   as	   a	   control	   for	   protein	   loading	   (C,	   bottom	  
panels).	  Frozen	  section	  of	  E10	  knockout	   (-­‐/-­‐)	  and	  wt	  embryos	  were	  stained	  with	  anti-­‐PKN2	  
mAb	   (R&D	   systems)	   and	   an	   Alexa-­‐488	   secondary	   antibody.	   DAPI	   counterstained	   embryos	  
were	  visualised	  by	  confocal	  microscopy	  (D).	  To	  visualise	  apical	  accumulation	  of	  PKN2,	  z-­‐stack	  
images	   were	   compiled	   as	   a	   projection	   (D,	   right	   hand	   panel).	  Whole	   mount	   x-­‐gal	   staining	  
reveals	   broadly	   ubiquitous	   expression	   in	   heterozygous	   embryos	   (E).	   Expression	   of	   PKN	  
isoform	  mRNA	  expression	  was	  assessed	  in	  E8	  embryo	  extracts	  by	  qPCR	  (F).	  PKN2	  disruption	  
is	   confirmed	   by	   loss	   of	   PKN2	   mRNA.	   No	   expression	   compensation	   of	   PKN1	   or	   PKN3	   was	  
observed	   on	   loss	   of	   PKN2.	   PKN1,	   PKN2	   and	   PKN3	  mRNA	   expression	   in	   E10	   embryos	   was	  
assessed	   by	   RNAscope	   in	   situ	   hybridisation	   as	   described	   in	   supplementary	   experimental	  
procedures	  (G).	  Broad	  expression	  of	  PKN1	  and	  PKN2	  can	  be	  seen	  in	  all	  tissues	  whereas	  PKN3	  
is	   restricted;	   open	  arrow	  heads	   indicate	  high	  PKN3	  expression	   in	   the	   endocardial	   lining	  of	  
the	  bulbus	  arteriosus.	  Abbreviations:	  nt,	  neural	   tube;	  pm,	  pharyngeal	  mesoderm;	  h,	  heart;	  
ba,	  branchial	  arch;	  m,	  mesenchyme.	  
	  


































Figure	   S3.	   PKN2	   knockout	   yolk	   sacs	   exhibit	   an	   immature	   vascular	   plexus	   and	   heart	  
development	   is	   retarded,	   related	   to	   figure	   1.	  Yolk	  sac	  endothelial	  cells	  were	  stained	  with	  
endomucin	  and	  anti-­‐LYVE-­‐1	  antibodies	  (A).	  Yolk	  sacs	  from	  E9.5	  embryos	  were	  also	  paraffin	  
embedded	  and	  stained	  with	  H&E	  (A,	  right	  hand	  panels).	  High	  magnification	  images	  of	  LYVE-­‐1	  
staining	   reveal	   endothelial	   protrusions,	   indicated	   by	   arrows	   (B).	   To	   examine	   the	   delay	   in	  
cardiac	  looping,	  E8.5	  embryos	  were	  whole	  mount	  stained	  for	  desmin	  and	  3D	  reconstructions	  
were	  processed	  using	  Bitplane	   Imaris	  software	  (C,	  upper	  panels).	  Transverse	  sections	  were	  
also	  stained	  for	  desmin	  followed	  by	  Alexa-­‐488	  secondary	  to	  reveal	  cardiomyocytes	  (C;	  lower	  
panels).	   (D)	  Whole	  mount	   staining	  of	   PKN2	  heterozygous	   and	   knockout	   embryos	   and	   yolk	  
sacs	  (ys)	  with	  desmin	  (blue	  -­‐	  Alexa	  647)	  and	  endomucin	  (green	  –	  Alexa	  488).	  Desmin	  stained	  
hearts	   (boxed)	   are	   un-­‐looped	   in	   the	   knockout	   embryos	   compared	   to	   littermates.	   Sections	  
were	  counterstained	  with	  DAPI.	  Histological	  H&E	  transverse	  sections	  through	  the	  head	  of	  an	  
E9.5	  PKN2	  knockout	  embryo	  revealed	  a	  fully	  open	  hind-­‐brain	  neural	  tube	  (E).	  Abbreviations	  
are:	  ys,	  yolk	  sac;	  otic	  v,	  otic	  vesicle;	  optic	  v,	  optic	  vesicle;	  nt,	  neural	  tube;	  dnt,	  dorsal	  neural	  
tube;	  fb,	  forebrain;	  as,	  aortic	  sac.	  
	  
	  





































































































Figure	   S4.	   Effects	   of	   PKN2	   deletion	   on	   actin	   organisation	   and	   LPA	   induced	   migration,	  
related	   to	   figure	   3.	   The	   actin	   cytoskeleton	   remains	   largely	   unaffected	   by	   4-­‐OHT	   induced	  
PKN2	  deletion	   (A).	  MEFs	  were	  methanol	   fixed	  and	   stained	  with	  anti-­‐PKN2	  mAb	  and	  alexa-­‐
488	   labelled	   secondary,	   and	   DAPI,	   prior	   to	   confocal	   imaging	   (left	   panels);	   4-­‐OHT	   induced	  
deletion	  of	  PKN2	  (left	  bottom	  panel).	  Following	  PFA	  fixation,	  F-­‐actin	  was	  stained	  with	  FITC-­‐
phalloidin	  (actin)	  and	  nuclei	  with	  DAPI	  (A,	  middle	  panels).	  Rac1	  and	  actin	  are	  localised	  at	  the	  
leading	   edge	  of	  migrating	   cells	   in	   PKN2	  expressing	  or	   PKN2	  deleted	   cells	   (A,	   right	   panels).	  
Cells	  were	  stained	  with	  anti-­‐Rac1	  mAb	  and	  alexa-­‐488	  labelled	  secondary,	  Alexa-­‐555	  labelled	  
phalloidin	  and	  DAPI.	   Single	   cell	   tracking	   reveals	   that	  PKN2	  deletion	   supresses	   LPA	   induced	  
migration	  speed	  of	  MEFs	  in	  scratch	  wound	  assays	  (B-­‐D);	  4-­‐OHT	  induced	  Cre	  activity	  reduces	  
migration	   of	   PKN2fl/fl	   but	   not	   PKN2wt	   cells.	   Box	   and	   whisker	   plots	   indicate	   the	   average,	  
quartiles	  and	  range	  of	   individual	  cell	  speed;	  *<P	  0.05;	  **p<0.01;***p<0.001	  ANOVA.	  Single	  
cell	  tracks	  from	  both	  wound	  edges	  are	  displayed	  for	  the	  iCre-­‐PKN2fl/fl	  cells	  (D;	  axes	  indicate	  





(male and female) 
Age Offspring/ 
Embryos 




- 91 21 44 26 
PKN3 +/-  
 
- 168 43 87 38 
PKN1 +/- PKN3 +/- 
 
- 222 20 190 12 
PKN2tm1a +/- 
 
- 171 81 90***† 0*** 
PKN2tm1c +/fl 
 
- 36 11 18 7 
PKN2tm1a +/- 
 
E8.5 30 9 13 8 
PKN2tm1a +/- 
 
E9.5 76 22 34 20 
PKN2tm1a +/- 
 
E10.5 23 6 15 2 
PKN2tm1a +/- 
 
E11.5+ 56 15 41 0*** 
 
 
Table S1. Disruption of the three PKN genes in mouse reveals that PKN2 is 
essential in development, related to figure 1. All mice are on a C57B/6J 
background. For PKN1 +/- PKN3 +/- double het crosses, wild-type and knockout 
numbers refer to homozygosity at both alleles; heterozygous numbers indicate 
heterozygosity at either allele. PKN2tm1a is a knockout first allele (KOMP), which is 
converted to a floxed (fl) conditional allele by flp recombinase to give pkn2tm1c. †On 
this background there was a partially penetrant haplo-insufficiency despite adult	  wt	  
and	   heterozygous	   mice	   being	   fertile,	   normal	   weight	   and	   overtly	   indistinguishable. 
Statistically significant deviation for expected numbers are indicated by asterisks; 






Cre negative Cre positive 





8 9 16 12 
SM22-Cre+/-PKN2fl/+ 
x PKN2fl/fl 






16 2 5 4 5 
E11.5 
 
19 5a 6 13 4b 
E13.5 
 
8 3 2 1 2 
E9.5-
13.5 
52 10 13 18 11 
Expected Fraction: 0.25 0.25 0.25 0.25 	  
 
Table S2. Conditional PKN2 knockout offspring and embryo numbers, related 
to figure 2. All mice are on a C57B/6J background. Statistically significant deviation 
for expected numbers are indicated by asterisks; ***P < 0.001; χ2 test. aone embryo 
malformed and dead; bone embryo small and dead. 	  
Gene	  name	  and	  phosphorylation	  site	  identified/Protein	  
































































Pkn2 pS582: Deleted following 4-OHT treatment. 
 	  	   	  	   	  	   **	   55.3	  
Zc3hc1 pS394: NIPA; E3 ligase complex 
component – mitotic entry. 	  	   	  	   	  	   **	   17.6	  
Anln pS180: Anillin; structural integrity of cleavage 
furrow – cytokinesis. 	  	   ***	   	  	   ***	   12.9	  
Top2a pT1350: Topoisomerase 2; chromosome 
segregation –mitosis. 	  	   ***	   	  	   **	   11.3	  
Tpx2 pS486: Spindle assembly factor and 
microtubule nucleation – mitosis. 	  	   	  	   	  	   *	   8.5	  
Anln pS293: Anillin; structural integrity of cleavage 
furrow – cytokinesis. 	  	   *	   	  	   *	   7.9	  
Tpx2 pS737: Spindle assembly factor and 
microtubule nucleation – mitosis. 	  	   *	   	  	   *	   6.2	  
Ska3 pS154: Kinetochore complex component – 
mitsosis. 	  	   *	   	  	   **	   5.6	  
Pkn2 pS619: Deleted following 4-OHT treatment. 
 	  	   **	   	  	   *	   5.3	  
Rgcc pS97: Regulator of Cell Cycle; enhances cdk1 
activity – cell cycle. 	  	   *	   	  	   **	   4.9	  
Arpp19 pS23: cAMP regulated pp19; mitotic PP2A 
inhibitor - mitosis  	  	   ***	   	  	   **	   4.7	  
Anln pS180: Anillin; structural integrity of cleavage 
furrow – cytokinesis. 	  	   **	   	  	   *	   4.3	  
Lig1 pS49: DNA ligase 1; seals nicks during DNA 
replication – S-phase. 	  	   **	   	  	   **	   4.2	  
Cep55 pS428: Centrosomal protein required for 
mitotic exit - mitosis 	  	   *	   	  	   ***	   3.8	  
Lig1 pT77: DNA ligase 1; seals nicks during DNA 
replication – S-phase. 	  	   	  	   	  	   	  	   3.6	  
Ercc6l pS1021: Spindle checkpoint helicase binding 
Mad2 – mitosis. 	  	   **	   	  	   *	   3.4	  
Lig1 pS51: DNA ligase 1; seals nicks during DNA 
replication – S-phase. 	  	   **	   	  	   **	   3.2	  
Lig1 pS188: DNA ligase 1; seals nicks during DNA 
replication – S-phase. 	  	   *	   	  	   **	   2.8	  
Mcm3 pS672: DNA replication licencing factor – 
replicative helicase – S-phase. 	  	   	  	   	  	   ***	   2.6	  
Ncapd2 pS1320: Condensin complex subunit 1 – 
mitosis. 	  	   **	   	  	   *	   2.6	  
Mcm3 pS672: DNA replication licencing factor – 
replicative helicase – S-phase 	  	   *	   	  	   **	   2.5	  
Mcm2 pS41: DNA replication licencing factor – 
replicative helicase – S-phase 	  	   	  	   	  	   *	   1.7	  
Mcm2 pS21: DNA replication licencing factor – 
replicative helicase – S-phase 	  	   *	   	  	   *	   1.7	  
Hmga2 pS101 pS104: Transcriptional regulator - 
cell cycle 	  	   *	   	  	   	  	   0.8	  
Pard3 pS174: Cell polarisation complex protein – 
cell cycle. 	  	   *	   	  	   	  	   0.7	  
Pard3 pS221: Cell polarisation complex protein – 
cell cycle. 	  	   	  	   	  	   *	   0.6	  
Mcm2 pT39 pS41: DNA replication licencing factor; 
helicase – S-phase. 	  	   *	   	  	   	  	   0.5	  
Hmga2 pT99 pS100 pS101: Transcriptional 
regulator - cell cycle 	  	   	  	   	  	   **	   0.4	  
Arhgef2 pS955: Rho GTPase exchange factor 
regulating division – mitosis.  	  	   	  	   	  	   **	   0.1	  
	  
 
-­‐5	   -­‐4	   -­‐3	   -­‐2	   -­‐1	   0	   1	   2	   3	   4	   5	  
	  
-­‐4	   -­‐3	   -­‐2	   -­‐1	   0	   1	   2	   3	   4	   5	  
	  
Key: Relative Fold Change 
 
 
Table S3. Summary of cell cycle and mitosis associated phosphopeptides 
significantly modulated by PKN2 deletion, related to figure 3. PKN2 iMEFs were 
treated with 4-OHT or Vehicle, cultured for 48 hours to allow PKN2 loss, serum 
starved overnight and, where indicated, re-stimulated with serum for 30 minutes prior 
to cell lysis. Phosphopeptides were analysed by LC-MS/MS across 4 biological 
replicates. Hits are compiled from combined cell division (GO:0051301), mitosis 
(GO:0007067) and cell cycle (GO:0007049) ontologies. Only peptides significantly 
modulated by PKN2 loss are included and hits are ordered according to average fold 
change after 10% serum re-stimulation. Colours represent phosphopeptide 
abundance relative to the sum of the four conditions. Asterisks indicate significant 
differences between Vehicle and 4-OHT treatments under either serum free or serum 
stimulated conditions as indicated; Benjamini & Hochberg corrected p-values: * 
<0.05; **<0.01; ***<0.001. 
 
 
	  Gene	  name	  and	  phosphorylation	  site	  identified/Protein	  
name/Description	  and	  processes	  regulated.	  































































Anln	  pS180:	  Anillin; actin binding protein that 
regulates cytoskeletal dynamics.	  
	  	   ***	   	  	   ***	   12.9	  
Anln	  pS293:	  Anillin; actin binding protein that 
regulates cytoskeletal dynamics.	  
	  	   *	   	  	   *	   7.9	  
Myo18a	  pS83:	  Myosin 18a; modulates lamellar 
actomyosin - cell protrusion and migration	  
	  	   **	   	  	   *	   3	  
Ppp1r18	  pS212:	  Protein Phosphatase 1, Regulatory 
Subunit 18; targets PP1 to F-actin	  
	  	   	  	   	  	   *	   2.5	  
Map1b	  pS1293	  pS1307:	  Microtubule-Associated 
Protein 1B; microtubule assembly 	  
	  	   **	   	  	   **	   2.4	  
Nes	  pS169:	  Nestin; intermediate filament protein - 
cytoskeleton	  
	  	   **	   	  	   *	   2.4	  
Flna	  pS1084:	  Filamin A; actin-binding protein, links 
actin to membrane 	  
	  	   *	   	  	   ***	   2.3	  
Cgn	  pS131:	  Cingulin; actin binding – cytoskeletal 
dynamics	  
	  	   *	   	  	   	  	   2.2	  
Nes	  pS731: Nestin; intermediate filament protein – 
cytoskeletal dynamics	  
	  	   *	   	  	   ***	   2	  
Nes	  pS688: Nestin; intermediate filament protein – 
cytoskeletal dynamics	  
	  	   **	   	  	   **	   2	  
Nes	  pS623: Nestin; intermediate filament protein – 
cytoskeletal dynamics 
	  	   *	   	  	   **	   1.8	  
Zyx	  pS336:	  Zyxin; concentrates at focal adhesions – 
cytoskeletal organization	  
	  	   	  	   	  	   *	   1.6	  
Palld	  pS782:	  Palladin; component of actin-containing 
microfilaments - cytoskeletal dynamics	   	  	   	  	   	  	   **	   1.6	  
Fhod1	  pS502:	  Formin Homology 2 Domain 
Containing 1; Role in assembly of F-actin structures	  
	  	   	  	   	  	   **	   0.9	  
Svil	  pS960:	  Supervillin; links actin cytoskeleton and 
the membrane – cytoskeletal dynamics	  
	  	   	  	   	  	   *	   0.7	  
Epb41l1	  pS782:	  Erythrocyte Membrane Protein Band 
4.1-Like 1 – actin binding	  
	  	   *	   	  	   **	   0.7	  
Ssh3	  pS639:	  Slingshot Protein Phosphatase 3 – actin 
filament dynamics	  
	  	   **	   	  	   ***	   0.4	  
Ppp1r18	  pS224: Protein Phosphatase 1, Regulatory 
Subunit 18; targets PP1 to F-actin	  
	  	   	  	   	  	   *	   0.3	  
Myo1h	  pT356	  pS364	  pS365:	  Myosin-1H; actin-based 
motor molecules with ATPase activity	  
	  	   	  	   	  	   **	   0.2	  
Arhgef2	  pS955:	  Rho/Rac Guanine Nucleotide 
Exchange Factor (GEF) 2; Activates Rho-GTPases 	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Table S4. Summary of cytoskeleton, intermediate filament and focal adhesion 
associated phosphopeptides significantly modulated by PKN2 deletion, related 
to figure 3. PKN2 iMEFs were treated with 4-OHT or Vehicle, cultured for 48 hours 
to allow PKN2 loss, serum starved overnight and, where indicated, re-stimulated with 
serum for 30 minutes prior to cell lysis. Phosphopeptides were analysed by LC-
MS/MS across 4 biological replicates. Hits are compiled from combined actin 
cytoskeleton (GO:0031523; GO:0003779), focal adhesion (GO:0005925), 
microtubule (GO:0001578) and intermediate filament  (GO:0005882) ontologies. 
Only peptides significantly modulated by PKN2 loss are included and hits are 
ordered according to average fold change after 10% serum re-stimulation. Colours 
represent phosphopeptide abundance relative to the sum of the four conditions. 
Asterisks indicate significant differences between Vehicle and 4-OHT treatments 
under either serum free or serum stimulated conditions as indicated; Benjamini & 
Hochberg corrected p-values: * <0.05; **<0.01; ***<0.001. 
 
 
SUPPLEMENTARY	  EXPERIMENTAL	  PROCEDURES	  
	  
Mice	  
To	   generate	   PKN1	   null	  mice,	   a	   HindIII/SpeI	   fragment	   of	   the	   PKN1	   genomic	   sequence	  was	  
cloned	   and	   an	   IRES/β-­‐Galactosidase/neomycin	   cassette	  was	   introduced	   into	   a	   SmaI	   site	   in	  
the	   second	  exon;	  PKN1	  has	   two	  alternate	   transcripts	  which	  differ	   in	   their	   first	   exon	  usage	  
(termed	  1a	   and	   1b)	   and	   the	   disrupted	   exon	   is	   the	   first	   exon	   common	   to	   both	   transcripts.	  
PKN1	   targeted	   GK129	   Embryonic	   Stem	   clones	   (PKN1+/-­‐)	   were	   isolated	   and	   injected	   into	  
C57BL/6	  blastocysts	   to	   generate	   chimeras.	   Several	   chimeras	   gave	  germ	   line	   transmissions,	  
which	   were	   used	   to	   establish	   the	   homozygous	   PKN1-­‐deficient	   mouse	   line.	   Mice	   were	  
backcrossed	   onto	   C57BL/6	   for	   a	  minimum	  of	   6	   generations.	  Genotypic	   characterization	   of	  
recombinant	   ES	   cells	   and	   adult	   mice	   was	   confirmed	   by	   Southern	   blot	   analysis	   of	   KpnI-­‐
digested	  genomic	  DNA.	  Mice	  were	  genotyped	  from	  ear	  clip	  genomic	  DNA	  with	  PKN1	  specific	  
sense	   (PKN1-­‐F;	   5’-­‐AGAGCACTATGTGTTTTTAGCTGCTGAGCC-­‐3’)	   and	   antisense	   (PKN1-­‐R;	   5’-­‐
TGTCCTTAGGTATCTGGTGACAGTGTGGG-­‐3’)	  primers	  and	  an	   IRES	  cassette	  antisense	   (IRES-­‐R;	  
5’-­‐GCTAGACTAGTCTAGCTAGAGCGGCC-­‐3’)	   to	   generate	   a	   900bp	   fragment	   for	   the	   wt	   locus	  
(PKN1-­‐F	  with	  PKN1-­‐R)	  and	  a	  450bp	  fragment	  for	  the	  PKN1	  ko	  locus	  (PKN1-­‐F	  with	  IRES-­‐R).	  	  
	  
To	  generate	  PKN3	  null	  mice,	  a	  fragment	  of	  the	  PKN3	  genomic	  sequence	  was	  subcloned	  from	  
a	  BAC	  clone	  (BACPAC	  RP24-­‐364D12)	   into	  the	  NotI	  and	  XhoI	  sites	  of	  pFlrt	   (Ralf	  Adams);	   the	  
PKN3	   fragment	   was	   bounded	   by	   the	   forward	   cloning	   primer,	   SHA-­‐NotI-­‐F	   (5’-­‐
ATAAGAATGCGGCCGCGTTACCGTGGAATATGCCACCG-­‐3’)	   and	   a	   naturally	   occurring	   XhoI	   site	  
situated	   between	   exon	   15	   and	   exon	   16	   of	   PKN3.	   The	   coding	   sequence	   of	   Exon	   2	   was	  
replaced	  by	  a	  PGK-­‐neo	  cassette,	   to	  generate	   the	  PKN3	  targeting	  construct	  using	   the	  Quick	  
and	   Easy	   Conditional	   Knockout	   Kit	   (Gene	   Bridges)	   according	   to	   the	   manufacturers	  
instructions.	   PKN3	   targeted	   Primogenix	   B6.1	   (C57Bl/6N)	   ES	   cells	   were	   identified	   by	   PCR	  
screening	   and	   injected	   into	   C57Bl/6	   blastocysts	   to	   generate	   chimeras	   and	   germ	   line	  
transmission.	  Correct	  integration	  was	  confirmed	  by	  multiple	  diagnostic	  PCR	  of	  genomic	  DNA	  
using	   primers	   flanking	   both	   the	   short	   and	   long	   homology	   arms	   of	   the	   PKN3	   knockout	  
construct.	  Mice	  were	  genotyped	  from	  earclip	  genomic	  DNA	  using	  PKN3	  specific	  sense	  (PKN3-­‐
F3;	   5’-­‐	   CCAGAAGGCACTGGGCGAAC	   -­‐3)	   and	   antisense	   (PKN3-­‐R1;	   5’-­‐	  
CAACACAAGGCTAGAGTTCA	  -­‐3)	  primers	  to	  generate	  a	  540bp	  fragment	  for	  the	  wt	  locus	  and	  a	  
2kb	  fragment	  for	  the	  ko	  locus.	  
	  
To	   generate	   PKN2	   null	   mice	   targeted	   ES	   cells	   were	   obtained	   from	   the	   KOMP	   Repository	  
(www.komp.org:	  Project	   ID66263	   -­‐	  pkn2	  MGI:109211).	   Two	   independent	   knockout	   first	   ES	  
cell	  clones	  underwent	  germline	  transmission:	  clone	  G05	  (allele:	  Pkn2tm1a(KOMP)Wtsi)	  and	  clone	  
G08	   (allele:	   Pkn2tm1e(KOMP)Wtsi).	   Clone	   G08	   has	   lost	   the	   3’	   loxP	   site	   necessary	   to	   allow	  
generation	  of	  a	  conditional	  mouse	  through	  FLP/FRT	  recombination	  so	  provides	  a	  null	  allele	  
only.	  Mice	  were	  genotyped	  from	  ear	  clip	  genomic	  DNA	  with	  PKN2	  specific	  sense	  (PKN2-­‐F2;	  
5’-­‐	   GGTTTGGTGACCAGTAAAAACTG	   -­‐3’)	   and	   antisense	   (PKN2-­‐R1;	   5’-­‐
GGAATACAGAACAAGGCAAAAGC	  -­‐3’)	  primers	  and	  an	  insert	  specific	  antisense	  primer	  (En2R;	  
5’-­‐CCAACTGACCTTGGGCAAGAACAT	  -­‐3’)	  to	  generate	  a	  1089bp	  fragment	  for	  the	  wt	  locus	  and	  
a	  395bp	  fragment	  for	  the	  PKN2	  ko	  locus.	  To	  convert	  the	  PKN2	  to	  a	  conditional	  allele,	  PKN2	  
heterozygous	  mice	  were	  crossed	  with	  a	  Flp	  deleter	  mouse	  (Tg(CAG-­‐Flpo)1Afst;	  background	  
C57Bl/6N);	   to	   genotype,	   sense	   primer	   PKN2-­‐F2	   was	   used	   with	   a	   second	   gene	   specific	  
antisense	  primer	   (PKN2-­‐R2;	  5’-­‐	  CTGAAGACACTTTGAAAAGGATG	   -­‐3’)	   to	  generate	  489bp	  and	  
635bp	  products	  for	  the	  wt	  and	  conditional	  alleles	  respectively.	  	  
	  
Tetraploid	   embryos	   for	   rescue	   experiments	   were	   generated	   by	   fusing	   2	   cell	   embryos	  
(B6CBAF1	   x	   F1)	   on	   the	  Cell-­‐fusion	   instrument,	   CF-­‐150B	   available	   from	   BLS	   Ltd.,	   Hungary.	  
Successfully	   fused	   embryos	   were	   held	   in	   culture	   and	   allowed	   to	   develop	   to	   the	   8	   cell	  
stage.	   	  8	   cell	   stage	   tetraploid	   embryos	   and	  PKN2	  embryos	   (stemming	   from	  heterozygote	   x	  
heterozygote	   matings)	  were	   rendered	   zona	   free	   with	   Acid	   Tyrodes	   solution	   before	  
aggregation	   of	   1-­‐2	   tetraploid	   embryos	   with	   each	   PKN2	   embryo	   according	   to	   standard	  
protocols	   (Nagy	   and	   Rossant,	   1993).	   Aggregated	   embryos	   were	   transferred	   into	  
pesudopregnant	  surrogate	  mice.	  
	  
Tie2-­‐Cre	   (Koni	   et	   al.,	   2001)	   and	   SM22α-­‐Cre	   mice	   (Lepore	   et	   al.,	   2005)	   on	   a	   C57BL/6	  
background	  were	   kindly	   provided	   by	   Taija	  Makinen	   and	   Ralf	   Adams.	   Rosa26CreERT2	  mice	  
(Gt(ROSA)26Sortm9(cre/ESR1)Arte)	   are	   from	   Taconic	   biosciences.	   Cre	   positive	   mice	   were	  
identified	  using	  Cre	  sense	  (Cre-­‐F;	  5’-­‐	  ACTATCCAGCAACATTTGGGCC	  -­‐3’)	  and	  antisense	  (Cre-­‐R;	  
5’-­‐	   CCGGCAAAACAGGTAATTCGG	   -­‐3’)	   primers	   to	   generate	   a	   450bp	   fragment.	   For	   in-­‐vivo	  
bromodeoxyuridine	   (BrdU)	   labeling	   SM22α-­‐Cre	   mice	   were	   injected	   with	   2mg	   BrdU	   i.p.	   2	  
hours	  prior	  to	  sacrifice. 
	  
Antibodies	  and	  Staining	  
Antibodies	   used	  were:	   PRK1	  mAb	   (BD	   biosciences),	   PKN2	  mAb	   (Clone	   509105;	   N-­‐terminal	  
epitope	   amino	   acids	   18-­‐207;	   R&D	   systems),	   PKN2	   mAb	   (Clone	   1D1;	   C-­‐terminal	   epitope	  
amino	   acids	   555-­‐718,	   Abcam),	   Tubulin	   mAb	   (Sigma;	   Clone	   B-­‐5-­‐1-­‐2),	   LYVE-­‐1	   (Reliatech	  
GmbH),	  PECAM-­‐1	  rat	  mAb	  (BD	  Biosciences),	  Desmin	  mAb	  (Dako),	  BrdU	  mAb	  (Dako),	  caspase	  
3	   (R&D	   systems),	   Annexin	   V	   (Biolegend),	   phospho-­‐Histone	   H3	   S10	   (EMD	   Millipore),	   anti-­‐
endomucin	   rat	   mAb	   (Santa	   Cruz),	   GAPDH	   (Santa	   Cruz),	   Cyclin	   A	   (Santa	   Cruz),	   Cyclin	   D1	  
(Spring	   Bioscience),	   PCNA	   (Oncogene	   Research	   Products),	   Mcm2	   (Bethyl)	   and	   phospho-­‐
specific	   polyclonal	   antibodies	   (PRK1/2	   T744,	   ERK,	   Akt,	   p70S6K,	   cdk1	   Y15,	   eIF4E	   S209;	   Cell	  
Signaling	   Technology).	   Secondary	   HRP	   (Amersham)	   and	   Alexa	   488/555/647	   (Invitrogen)	  
antibodies	  were	  used	  as	  appropriate.	  For	  immunostaining,	  embryos	  were	  fixed	  overnight	  in	  
10%	   neutral	   buffered	   formalin,	   embedded	   in	   paraffin;	   4µm	   sections	   were	   treated	   with	  
sodium	   citrate	   (pH	   6.0)	   buffer	   prior	   to	   immunostaining.	   HRP-­‐secondary	   antibodies	   were	  
developed	  with	  3,3’-­‐diaminobenzidine	  (DAB).	  Fluorescently	  stained	  sections	  were	  incubated	  
for	  30	  minutes	  in	  0.1	  %	  Sudan	  Black	  in	  70%	  EtOH	  and	  mounted	  in	  Hardset	  mount	  with	  DAPI	  
(Vector).	   For	  β-­‐galactosidase	   staining,	   embryos	  were	   fixed	   in	   0.4%	   paraformaldehyde	   and	  
stained	  using	  X-­‐gal	  according	  to	  standard	  protocols.	  For	  standard	  histological	  analysis	  4µm	  
sections	  were	  stained	  with	  hematoxylin	  and	  eosin	  (H&E).	  For	  frozen	  sections,	  embryos	  were	  
embedded	  and	   frozen	   in	  OCT.	  8mm	  sections	  were	  dried	  at	   room	   temperature	   for	  30	  min,	  
permeabilized	  with	   0.1%	  Triton-­‐x100	   for	   10	  min,	   blocked	   in	   PBS-­‐BSA	  2%	  and	   stained	  with	  
anti-­‐PKN2mAb	   (R&D	   systems),	   alexa488	   secondary	   and	   DAPI.	   Images	   were	   acquired	   on	   a	  
Nikon	   Eclipse	   90i	   upright	   microscope	   or	   Zeiss	   LSM	   confocal	   and	   processed	   using	   NIS-­‐
elements	  software,	  Zen	  and	  Adobe	  Photoshop	  CS5.	  
	  
For	   whole-­‐mount	   staining,	   embryos	   were	   dissected,	   fixed	   in	   4%	   PFA,	   permeabilised	   with	  
0.5%	  triton	  X100,	  blocked	  with	  PBSMT	  (PBS	  supplemented	  with	  3%	  milk	  and	  0.1%	  Tween	  20)	  
and	  stained	  overnight	  with	  appropriate	  primary	  antibodies.	  For	  PECAM	  stains	  embryos	  were	  
then	   washed	   and	   incubated	   overnight	   with	   a	   peroxidase-­‐conjugated	   goat	   anti-­‐rat	   IgG	  
(Pierce),	  washed	  and	  developed	  with	  Substrate	  G	  (Vector)	  and	  cleared	  in	  glycerol,	  based	  on	  
published	   protocols	   (Adams	   et	   al.,	   1999).	   Images	   were	   acquired	   on	   a	   Nikon	   Eclipse	   90i	  
upright	   microscope	   and	   processed	   using	   NIS-­‐elements	   software.	   For	   fluorescent	   staining	  
appropriate	  alexa	  488/555/647	  were	  used	  as	   indicated	  and	  confocal	   images	  were	  acquired	  
on	  a	   Zeiss	   LSM	  710/780	   inverted	  microscope	  and	  processed	  using	   ImageJ,	   Zen	  and	  Adobe	  




For	   PKN1,	   PKN2	   and	   PKN3	   in-­‐situ	   staining,	   an	   RNAscope	   2.0	   FFPE	   assay	   kit	   was	   used	  
(Advanced	  Cell	  Diagnostics)	  according	  to	  the	  manufacturers	  instructions.	  The	  sections	  were	  
incubated	   with	   RNAscope	   custom	   oligonucleotide	   probes:	   Mouse	   PKN1,	   accession	   no.	  
NM_001199593.1,	  target	  region	  384-­‐1432;	  mouse	  PKN2,	  accession	  no.	  NM_178654.4,	  target	  
region	  634-­‐1628;	  mouse	  PKN3,	  accession	  no.	  NM_153805.1,	  target	  region	  401-­‐1352.	  Probes	  
were	   incubated	   for	   2	   hours	   at	   40°C	   and	   signals	   developed	   according	   to	   manufacturers	  
instructions	   using	   the	   RNAscope	   2.0	   HD	   Assay-­‐	   BROWN	   system	   and	   hematoxylin	  
counterstain.	  Whole-­‐mount	  in-­‐situ	  staining	  of	  ErbB3	  was	  carried	  out	  as	  elsewhere	  described	  
(Pryor	  et	  al.,	  2014).	  
	  
Cells	  and	  treatments	  
For	  siRNA	  depletion	  of	  mouse	  PKN3,	  EOMA	  cells	  were	  transfected	  using	  10	  nM	  Dharmacon	  
ON-­‐TARGET	  plus	  siRNA	  smartpool	  (4	  duplexes:	  #1:	  5’-­‐	  GCACCGACUUCGAGUAGAG	  -­‐3’;	  #2:	  5’-­‐	  
GGAAGGAAUUGGCUUUGGU	   -­‐3’;	   #3:	   5’-­‐	   GGACACUUGUGAAACCUAU	   -­‐3’;	   #4:	   5’-­‐	  
GUACAAAGGAACAGGGAAA	   -­‐3’)	   using	   HiPerfect	   (Qiagen).	   Cells	   were	   harvested	   after	   48	  
hours	  and	  examined	  by	  immunoblot.	  Mouse	  lung	  endothelial	  cells	  (MLEC)	  were	  isolated	  and	  
cultured	   as	   described	   by	   Reynolds	   et	   al	   (Reynolds	   and	   Hodivala-­‐Dilke,	   2006).	   For	   mouse	  
embryonic	  fibroblasts	  (MEF),	  embryos	  were	  decapitated	  and	  foetal	  liver	  was	  removed	  prior	  
to	   trypsin	   digestion	   and	   serial	   passage	   in	   DMEM	  with	   10%	   FBS.	   Lines	   were	   immortalised	  
using	   a	   3T3	   protocol	   of	   serial	   passage	   and	   subsequent	   senescence	   escape.	   ES	   cells	   were	  
isolated	  from	  blastocysts	  collected	  from	  heterozygous	  PKN2fl/+	  RosaCreERT	  crosses	  to	  enable	  
inducible	   knockout	  of	  PKN2	   in	   culture.	   Cells	  were	  derived	  as	  described	   (Bryja	  et	   al.,	   2006)	  
with	   the	   addition	  of	   a	  MEK	   inhibitor	   (PD0325901)	   for	   the	   initial	   stages	   to	   improve	  plating	  
efficiency.	   After	   4	   passages	   the	   cells	   were	   grown	   in	   standard,	   serum	   containing	   ES	   cell	  
media.	  Male	   cell	   lines	  with	   a	   good	   chromosome	   count	  were	   selected.	   Induction	   of	   Cre	   in	  
RosaCreERT	   cells	   was	   achieved	   through	   incubation	   with	   4-­‐hydroxytamoxifen	   (4-­‐OHT;	  
typically	  100nM)	  for	  1	  hour	  prior	  to	  media	  replacement.	  
	  
Immunoblotting	  
Lysates	  were	   resolved	  by	   SDS	  page	  and	   transferred	   to	  PVDF	  or	  nitrocellulose	  membranes.	  
Immunoblots	   were	   blocked	   in	   TBST	   (TBS	   containing	   0.1%	   Tween	   20)	   with	   3%	   BSA	   and	  
probed	   with	   primary	   antibodies	   as	   indicated.	   Following	   incubation	   with	   appropriate	   HRP	  
conjugated	  secondary	  antibodies	  (Amersham),	  bands	  were	  visualised	  by	  ECL	  using	  an	  Image	  
Quant	  digital	  imaging	  system	  (GE	  healthcare)	  or	  X-­‐ray	  film.	  	  
	  
Cell	  Growth	  and	  viability	  
Cell	  growth	  was	  assessed	  by	  cell	   counting,	  MTT	   (Methylthiazolyldiphenyl-­‐tetrazolium),	  and	  
FACs	  analysis.	  For	  MTT	  assays,	  cell	  grown	  in	  96	  well	  plates	  were	  incubated	  with	  1mM	  MTT	  
(Sigma)	  for	  1	  hour	  prior	  to	  DMSO	  solubilisation	  of	  formazan	  product	  and	  550nm	  absorbance	  
measurement	   (Tecan).	   For	   cell	   colony	   staining,	   monolayers	   were	   fixed	   with	   4%PFA	   and	  
incubated	  with	  0.1%	  Crystal	  Violet	  for	  30	  minutes.	  	  
	  
Cell	  cycle	  and	  apoptosis	  
For	  cell	  cycle	  and	  subG1	  analysis,	  cells	  were	  fixed	  in	  ice	  cold	  70%	  ethanol,	  washed	  with	  PBS	  
and	  RNAse	  A	  treated	  prior	  to	  staining	  with	  propidium	  iodide.	  For	  5-­‐Bromo-­‐2´-­‐Deoxyuridine	  
(BrdU)	   analysis,	   cells	  were	   incubated	   in	   culture	  with	  10µM	  BrdU	  prior	   to	   ethanol	   fixation,	  
acid	   treatment	   (2M	   HCl)	   and	   anti-­‐BrdU	   mAb	   followed	   by	   alexa-­‐488	   secondary	   staining.	  
Mitotic	   nuclei	   were	   stained	   with	   anti-­‐phospho-­‐Histone	   H3	   (S10)	   antibody	   and	   alexa-­‐488	  
secondary.	  For	  BrdU	  and	  mitotic	  assays,	  cell	  cycle	  was	  simultaneously	  assessed	  as	  described	  
above.	  To	  measure	  apoptosis,	  cells	  were	  stained	  with	  alexa-­‐647	  conjugated	  anti-­‐annexin	  V	  
antibody	  (Biolegend)	  and	  propidium	  iodide	  in	  appropriate	  buffer	  (10	  mM	  HEPES,	  pH	  7.4;	  140	  
mM	   NaCl;	   2,5	   mM	   CaCl2).	   Data	   were	   acquired	   on	   an	   LSRII	   fortessa	   (BD	   biosciences)	  
and	  analysed	  using	  FlowJo.	  
	  
Cell	  Motility	  
For	  migration	  analysis,	   confluent	  cell	  monolayers	  were	  scratch	  wounded	   in	  96	  well	   format	  
using	   a	   96-­‐well	   Wound–maker	   (Essen).	  Wound	   closure	   was	   followed	   by	   time-­‐lapse	   video	  
capture	  on	  an	  Essen	  IncuCyte.	  Individual	  cells	  were	  tracked	  using	  the	  Manual	  Tracking	  plugin	  
for	  ImageJ.	  A	  combined	  minimum	  of	  thirty,	  non-­‐mitotic	  cells	  migrating	  from	  opposing	  edges	  
of	  the	  scratch	  were	  tracked	  from	  three	  experimental	  repeats	  for	  each	  condition.	  
	  
RT-­‐PCR	  
RNA	  was	   isolated	  from	  mouse	  lungs	  and	  embryos	  using	  the	  RNeasy	  (Qiagen)	  RNA	  isolation	  
system	   and	   converted	   to	   cDNA	   using	   TaqMan	   (Applied	   Biosystems)	   reverse	   transcription	  
reagents.	  Specific	  primers	  spanning	  intron	  exon	  boundaries	  for	  PKN1	  and	  PKN3	  were	  used	  to	  
assay	   disruption	   of	   transcripts	   in	   PKN1	   and	   PKN3	   knockout	   mice.	   PKN2	   was	   used	   as	   an	  
internal	   control.	   Specific	   primers	   used	   were:	   PKN1,	   sense	   5’-­‐	   GCGACGCCGTACAGAGTGA	   -­‐
3’and	   antisense	   5’-­‐	   CTGCAAGGGATTGGGTAGCA	   -­‐3’	   (336bp),	   PKN2;	   sense	   5’-­‐	  
AGCGGCATGGCATGTGTCTCT	   -­‐3’and	   antisense	   5’-­‐	   TGCGTGCGTCAACGACTGGC	   -­‐3’	   (303bp)	  
and	   PKN3;	   sense	   5’-­‐	   GAGCCCCCAAGGATGAGAAA	   -­‐3’and	   antisense	   5’-­‐	  
AGTGTCCCTGTCAAGGCAATAG	   -­‐3’	   (790bp).	   For	   real-­‐time	   quantitative	   assessment	   of	   PKN1,	  
PKN2	  and	  PKN3,	  cDNA	  was	  amplified	  with	  Sybr	  Green	  PCR	  Master	  Mix	  (Applied	  Biosystems).	  
Data	   were	   normalized	   using	   the	   DeltaDeltaCt	   method	   with	   GAPDH	   as	   the	   housekeeping	  
gene,	  and	  expressed	  as	  the	  relative	  mRNA	  level	  compared	  to	  the	  control.	  Primers	  used	  were:	  
PKN1,	  sense	  5’-­‐ATCCGGCACACTGGAGACA-­‐3’	  and	  antisense	  5’-­‐	  TGGTGGATTCATGGGTTGGAG	  
-­‐3’;	   PKN2,	   sense	   5’-­‐	   CTGTGCCTGCAACAGTGC	   -­‐3’	   and	   antisense	   5’-­‐
CTGTAGAGTCACTGGCCGGA-­‐3’,	   PKN3,	   sense	   5’-­‐CTTGGGAACCCCCAACCTTT-­‐3’	   and	   antisense	  




Following	   sample	   extraction	   and	   trypsin	   digestion	   of	   control	   and	   treated	   samples,	   TiO2	  
chromatography	  was	  used	  to	  enrich	  phosphopeptides(Montoya	  et	  al.,	  2011).	   Identification	  
and	  quantification	  of	   these	  phosphopeptides	  across	  quadruplicate	  samples	  was	  performed	  
by	   LC-­‐MS/MS	   as	   described	   elsewhere(Casado	   and	   Cutillas,	   2011;	   Rajeeve	   et	   al.,	   2014).	  
Statistical	   significance	   of	   phosphorylation	   site	   changes	   across	   conditions	   is	   assessed	   and	  
sites	   are	   selected	   with	   a	   Benjamini	   &	   Hochberg	   adjusted	   p-­‐value	   <0.05.	   Kinase	   substrate	  
enrichment	   analysis	   (KSEA)	  was	   used	   to	   infer	   kinase	   activity	   from	   the	   phosphoproteomics	  
data(Casado	  et	  al.,	  2013).	  Ontologies	  and	  pathways	  enriched	  in	  the	  phosphoproteomics	  data	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